Member Info for LovableLumax

Guys do you not think there is a reason they are not targeting movies and series’ post production? No it’s not because of infringing Mirriad’s patents or because mirriad is dominating the market with £1m to £2m FY revenue it’s because there isn’t massive potential due to rights issues. With TikTok etc there are fewer legal minefields because of the small number of creators. They don’t have lots of actors, agents and lawyers involved. If mirriad had a worthwhile business they would be increasing revenues in manual mode so brands can test ahead of programmatic launch. Demand falling as clearly a pain to get sign off as mentioned by TBTT over 12 months ago.

It also shows Mirriad’s patents aren’t that prohibitive as Ryff also demonstrated.

Wyn, WTF does that mean, none financially? If the shorter gets badly burnt it'll mean they've had to buy a fair whack more than they took their short out for which will mean the share price is higher so yes, on paper, that is good financially.

Wow after a Jan 1st start at 2.75p we end the year at 0.155p and with H1 revenues down to £390k and having guided £4m revenues in May we might get 50% of that top end or 25% at the low end. Finishing the year with less cash than last year and Sept guidance of a £4m loss next year (at that time it was £2.5m guidance for this year). Even if programmatic ready as of now H1 very slow and Allenby guided a £4m loss with programmatic so most will be realised in H1 so a cash injection will be needed. All that being said the LinkedIn likes continue so all is rosey!!

I may be wrong and Jan’s update might be superb wirh £2m hit and lots of orders hitting Q1 (not unweighted pipeline which means nothing as we’ve seen) and could mean a smaller raise or none at all as suddenly revenues go crazy. We’ll see but the main thing is LinkedIn activity.

They have much more potent and therefore exciting warheads to go after as per the pipeline. CC was appointed as head of Research November last year and recommended that. Given the amazing animal study results it seems like a wise move.

Hopefully P1B has begun and given the superb data so far recruitment should be fast. I’m sure many oncologists/clinicians would recommend this trial given the indications sensitive to dox and much fewer side effects.

LOTM, you’ve implied you'll buy more shares. You could have bought on Friday for less than your recent buy and aside from one or two all your buys have been lower than the last. Anyway, you've got So many shares than the CEO and have only known about mirriad for a year or less. With 13m+ shares rather than buying more why not wait and see if there's a raise soon? If not and they're suddenly making or will make lots of money and the share price rises it's all good as you have loads. If they need a raise it'll be discounted if they can get one away.

I met someone who leases lenses to productions in UK. Who knew that was a thing but lenses can cost 10s of thousands and mostly they’re leased. Anyway, I spoke about VPP and honestly it was a complete no-no. He said PP on the up through integration and that means post production PP (VPP) nearly impossible as the PP will have tight contracts whereby brands can’t be added after. As normal PP grows VPP nigh on impossible. Make sense. All the nonsense on here re Yellowstone a caseinpoint

* VPP can’t integrate brands into stories

“While the strikes contributed to decrease, this downtrend was anticipated before the strikes because streaming services and cable nets had already begun to cancel low-performing programs, as profit margins dwindled due to cord-cutting and streaming video subscriptions appeared to be peaking.”

Product placement spending worldwide is on pace to grow at a slightly slower 12.1% to $32.98 billion this year, which would mark the fourth consecutive year of double-digit growth, following the worst decline in pandemic-struck 2020, according to the 2024-2028 PQ Media’s global product placement forecast.

Overall TV still commands the lion’s share of product placement spending globally at 70.1% in 2023 and movies remain the second-largest platform (11.9%).

Movie integrations, the second largest platform category, generated $3.50 billion globally last year. While the number of new films produced in North America has increased from 333 in 2020 to 504 in 2023, this still pales in comparison to film production prior to the 2020 pandemic, as 792 films were released in 2019.

Nevertheless, 25% of the 504 films released in 2023 featured 10 or more product placements, led by “Gran Turismo” and “Dumb Money.”

Digital media was the fastest-growing placement category in 2023, rising 15.1%, followed by films (up 13.1%), and music (up 13.0%).

Brands have ratcheted up podcast integrations, such as “Electric Easy” often opening with placements like characters trying Bud Light. The print media and videogame categories posted decelerated single-digit growth in 2023.

While the US accounted for well over half of product placement spend in 2023, the rest of the world is gaining ground, with Brazil and Mexico both exceeding $2 billion in spending, Australia investing more than $1 billion, and Germany and the United Kingdom approaching $1 billion.

AI placements differ slightly from virtual brand integrations, like those placed via companies like Mirriad, as AI software allows viewers to click on integrated products and be sent to an e-commerce site to purchase the product.

However, most brands are still hesitant to use the new AI tech because many of the product placements are cameos (appearing in the background), rather than brand integrations in which the actors hold the products towards the camera and/or discuss them favorably in the dialogue.

There are also copyright issues if the original producers of the content are not contacted in advance for permission to use an AI placement.

PQ Media president and CEO Patrick Quinn said product placement has grown substantially because brand marketers have become more willing to invest in the creative integration of their products.

"While these key growth drivers will continue to favor product placement, some concerns have emerged, as expressed by PQ Media’s Global Opinion Leader Panel, that the number of placement opportunities will decline going forward, as evidenced by the 14% drop in the number of scripted programs produced for the 2023-24 season – only the second decline since ad-supported cable networks began producing original programming in 2007,” Quinn said

“While the strikes contributed to decrease, this downtrend was anticipated before the strikes because str

The SAB was re-jigged when Chris became CEO.

Although not everyone’s cup of tea. Myles’ take -

Avacta #AVCT's Phase 1b expansion study for #AVA6000 is getting underway now in the US, with a third well-known hospital in the US - MD Anderson Cancer Centre, Houston, Texas - joining the existing two hospitals already recruiting (MSK in New York, and Fred Hutchison in Seattle).

There's also another interesting bit of info. Last week, the Company stated in RNS:

"The Phase 1b cohorts will enroll patients in three disease-specific cohorts including: (1) triple negative breast cancer; (2) salivary gland cancer and (3) high grade soft tissue sarcoma."

Today however, we see that both ovarian carcinoma and urothelial carcinoma have been actively added to the conditions that will be studied in the P1b trial.

This begs the question, has Avacta secured a partner to fund these two additional indications through P1b?

Todays update states that a further c.100 patients will be dosed in P1b.

Recall that targeted oncology company, Forty Seven, was acquired for $4.9bn by Gilead in 2020. At the time, it had only dosed 62 patients in a P1b trial for its lead asset.

Clearly the pre | CISION science and the AVA6000 clinical results over the almost three and a half years to date have exceeded absolutely everyone's expectations.

At some point, eventually(!), this share price will react to the phenomenal progress made to date.

A reminder -

Virgilio Sacchini, is the Pre|CISION® platform of Avacta, a British life sciences firm, a good example of how new technology can expand the reach of highly potent cancer therapies?

Avacta is an incredible application of biomedical engineering. For a treatment to have most efficacy we need to have a very powerful medication, and to be sure that the medication targets the right cells. If you have a very powerful medication going everywhere in the body, of course it can go to the cancer cells, but it may also go to other healthy cells, creating toxicity. The new concept is to target only cancer cells.

Can Avacta limit the side effects of chemotherapy by going straight to the point?

Yes, it goes straight to the environment of the cancer cells. There are other technologies, but Avacta’s is a very interesting one that combines a well-known and very powerful chemotherapy medication called Doxorubicin with a special molecule which is able to target and concentrate it in the cancer environment. The cancer environment is different to normal, and finding this difference and targeting the medication based on this difference means targeting only the cancer to be treated and not the other organs. In the specific Avacta situation they discovered that in the environment between the cancer cells there is a special protein called a fibroblast activation protein (FAP) and with a special molecule they can target this FAP and put a very high concentration of Doxorubicin into the FAP targeted cancer environment. In this way they kill more cancer cells and spare the other organs, because the other organs don’t have a high concentration of that FAP, and for this reason are preserved from the toxicity of the chemotherapy.

How does this change your way of operating in your hospital?

We are experiencing different types of target treatment. One of the most tested target treatments in breast cancer and gastric cancer are the HER2 targeted medications. In some cells there is a gene producing a lot of this so-called HER2 protein that helps cancer cells to grow quickly, and they were able to develop a monoclonal antibody able to kill this protein, and once you kill this HER2 protein the cells would die. This treatment can improve the curability of breast cancer by 40% and for gastric cancer by more than 40%.

Is such targeted treatment also shorter in duration?

It is more or less the same in terms of how long the treatment lasts, but the intensity of the side effects is much less. This means that you can give less drug, because the drug concentrates more in the target tissue. It is like having a rocket with a nuclear bomb inside, and the rocket is directed right away to the cancer cells – not to the body, because it would destroy the body, but to the cancer cells – and therefore able to spare the other parts of the body. Avacta has an incredible technology, because the drug that they that are using called Doxorubicin is an incredible

I’m not sure about that as a different drug albeit using the same biomarker/MOA. The preclinical models certainly underpin the platform too but I suspect they’ll want to see some safety in human.

P1b is starting. FDA will allow other indications to start at P1b (beyond the 3) as it has seemingly agreed proof of concept has been proven in 60 odd people in various indications so others can be added and these will clearly be tumours sensitive to doxorubicin and a first line treatment and the new additions are. That’s pretty exciting and certainly underpins the platform albeit AVA6000.

Https://x.com/rah00084/status/1869633631859167449?s=46

P1a is over.

P1b has begun.

#AVCT is adding (unused) indications to the CT.gov site, whilst simultaneously removing indications which will no longer be accepted onto trial.

Clearly there must be a reason behind that.

Or else, why retain any indications beyond STS/SGC/TNBC?

For those saying these indications are not part of P1b now. Of course they are not.

Nobody is suggesting they are.

The suggestion is retained (but unused) indications can’t begin at any other stage than P1b.

Which is exactly how TNBC has found itself in P1b despite the indication never featuring/having been dosed in P1a.

This is all about proof of concept.

What’s more, it also means the FDA has approved P1b for multiple indications which have not yet been dosed.

I.e. The FDA is implicitly approving proof of concept.

Recall the story about the FDA asking AVCT to double check their safety data because it was too good to be true.

This share price is completely devoid of all reason.

When this tanker turns, and it will turn, try stopping it.

Avacta doesn’t need a huge injection of cash to have the audit signed off and to collect the most important data which will be efficacy. They’ll need 12 months from audit sign off so early April. £20m from DX and by then say at least £10m cash from £32.5m June (less one HCI cash payment) seems fair so yes the auditor will sign off but it’s reliant on DX sale. Once P1b published and assuming the chemistry continues to work as it has and assuming dox continued to work as it has for 40+ years there will be clear efficacy data with the 3 indications. They will have options aplenty I have no doubt.

What should be really encouraging is the expansion speed it’s not 3+3 and leading oncologists singing AVA6000’s praises should mean recruitment isn’t an issue. I suspect once the CT gov website is updated Avacta will update the market on the dosing regimens etc. The Peel Hunt note stated capital would be linked to data milestones which tells me they expect the DX sale and reduced cash burn to provide sufficient funds for audit sign off. I’m sure once DX is sold they’ll also inform the market of that. After a pretty horrendous year for holders we should start 2025 on a much stronger footing both from a data and trial perspective and financially.

Also there were several patients whose disease stabilised meaning they could continue well beyond the usual 4.5 months which given the patient population quite something. Many of the tumours were refractory having had multiple lines of treatment. The emerging data from expansion should be something, lots of dox getting to where it's needed on tumours sensitive to it.

Https://x.com/rah00084/status/1867883311701561800?s=46

Https://x.com/bmhltd/status/1867910319055724869?s=46